{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:59:40Z","timestamp":1792479580718,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4t Leipzig","id":[{"id":"https:\/\/ror.org\/03s7gtk40","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fluctuations represent a major therapeutic challenge in Parkinson\u2019s disease (PD) and become increasingly prevalent with disease progression. While oral and device-aided therapies (DAT) improve symptom control, patients continue to experience disabling OFF episodes, in particular early morning OFFs, delayed ON, and no-ON phenomena. Increasing evidence suggests that both motor and non-motor fluctuations are more common than previously recognized and contribute substantially to impaired quality of life. Fluctuations affect up to 50% of patients within five years of disease onset to eventually affect almost all patients with longer duration. Beside altered central pharmacodynamics, peripheral mechanisms such as dysphagia, gastroparesis, altered intestinal absorption, and microbiome-mediated levodopa degradation, contribute to fluctuations. Although oral adjunct medication and DAT reduce daily OFF-time, clinically meaningful OFF periods often persist. This is where on-demand therapies provide rapid symptom relief and address the limitations of conventional oral medication and DAT. Hence, more regular, even daily use of on-demand therapies may improve quality of life in patients with PD. However, the potential impact of on-demand therapies on non-motor OFF periods needs further investigation. Side effects, handling and economic considerations should be taken into account. This expert perspective concludes that given the high prevalence and clinical relevance of fluctuations, on-demand therapies may be considered as an integral component of standard PD management rather than solely as a rescue option in rare emergency situations. Implementation may be particularly beneficial for patients experiencing early-morning-OFFs, delayed and no-ONs but also predictable and unpredictable OFFs.<\/jats:p>","DOI":"10.1007\/s00702-026-03288-9","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:52:21Z","timestamp":1790250741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["On-demand therapies\u2013emergency medication or daily routine?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-6609","authenticated-orcid":false,"given":"David","family":"Weise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Gandor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"3288_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H (2018) Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord 33:900\u2013908","journal-title":"Mov Disord"},{"key":"3288_CR2","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa A, Odin P et al (2022) Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs 36:1269\u20131283","journal-title":"CNS Drugs"},{"key":"3288_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of parkinson disease: a review. JAMA 323:548\u2013560","journal-title":"JAMA"},{"issue":"1","key":"3288_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","volume":"8","author":"M Beckers","year":"2022","unstructured":"Beckers M, Bloem BR, Verbeek MM (2022) Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):56","journal-title":"NPJ Parkinsons Dis"},{"key":"3288_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mdc3.13593","volume":"10","author":"SA Castillo-Torres","year":"2023","unstructured":"Castillo-Torres SA, Lees AJ, Merello M (2023) Intermittent apomorphine use for off period rescue in Parkinson\u2019s disease: a pragmatic review of over three decades of clinical experience. Mov Disord Clin Pract 10:190\u2013208","journal-title":"Mov Disord Clin Pract"},{"key":"3288_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.14802\/jmd.25031","volume":"18","author":"HJ Chang","year":"2025","unstructured":"Chang HJ, Park J, Oh S et al (2025) Efficacy of levodopa\/benserazide dispersible tablets on delayed ON to the first morning dose in patients with Parkinson\u2019s disease with motor fluctuations: a multicenter, randomized, open-label, crossover trial. J Mov Disord 18:244\u2013252","journal-title":"J Mov Disord"},{"issue":"2","key":"3288_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O et al (2005) Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord Feb 20(2):224\u2013230","journal-title":"Mov Disord Feb"},{"key":"3288_CR8","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731\u20132742","journal-title":"Brain"},{"key":"3288_CR9","first-page":"1877718X2614327","volume":"10","author":"Q Damiens","year":"2026","unstructured":"Damiens Q, Mille V, Faure J et al (2026) Gastroparesis in Parkinson\u2019s disease: Diagnostic and clinical implications for optimizing pharmacological treatment. J Parkinsons Dis 10:1877718X261432743","journal-title":"J Parkinsons Dis"},{"key":"3288_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA de Bie","year":"2025","unstructured":"de Bie RMA, Katzenschlager R, Swinnen BEKS et al (2025) Update on treatments for Parkinson\u2019s disease motor fluctuations - an international Parkinson and movement disorder society evidence-based medicine review. Mov Disord 40:776\u2013794","journal-title":"Mov Disord"},{"key":"3288_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2001","unstructured":"Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA (2001) A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58:1385\u20131392","journal-title":"Arch Neurol"},{"key":"3288_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40120-022-00435-8","volume":"12","author":"M Fabbri","year":"2023","unstructured":"Fabbri M, Barbosa R, Rascol O (2023) Off-time treatment options for Parkinson\u2019s disease. Neurol Ther 12:391\u2013424","journal-title":"Neurol Ther"},{"key":"3288_CR13","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"3288_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/mds.29796","volume":"39","author":"STFM Frequin","year":"2024","unstructured":"Frequin STFM et al (2024) Long-term motor complications in the LEAP study. Mov Disord 39:975\u2013982","journal-title":"Mov Disord"},{"key":"3288_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"3288_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","volume":"71","author":"DG Grosset","year":"2020","unstructured":"Grosset DG, Dhall R, Gurevich T et al (2020) Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord 71:4\u201310","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.20248","volume":"19","author":"RA Hauser","year":"2004","unstructured":"Hauser RA, Deckers F, Lehert P (2004) Parkinson\u2019s disease home diary: further validation and implications for clinical trials. Mov Disord 19:1409\u20131413","journal-title":"Mov Disord"},{"key":"3288_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"G H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger G, Trenkwalder C (2024) Diagnosis and treatment of Parkinson\u00b4s disease (guideline of the German Society for Neurology). Neurol Res Pract 6:30","journal-title":"Neurol Res Pract"},{"key":"3288_CR19","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1002\/mds.70107","volume":"40","author":"G H\u00f6glinger","year":"2025","unstructured":"H\u00f6glinger G, Lingor P, H\u00f6llerhage M, Trenkwalder C (2025) Treatment options for motor fluctuations in Parkinson\u2019s disease. Mov Disord 40:2848\u20132849","journal-title":"Mov Disord"},{"key":"3288_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.parkreldis.2020.08.028","volume":"79","author":"JS Hui","year":"2020","unstructured":"Hui JS, Fox SH, Neeson W et al (2020) Open-label titration of apomorphine sublingual film in patients with Parkinson\u2019s disease and OFF episodes. Parkinsonism Relat Disord 79:110\u2013116","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR21","first-page":"100145","volume":"6","author":"SH Isaacson","year":"2022","unstructured":"Isaacson SH, Pahwa R, Pappert EJ, Torres-Russotto D (2022a) Evaluation of morning bradykinesia in Parkinson\u2019s disease in a United States cohort using continuous objective monitoring. Clin Park Relat Disord 6:100145","journal-title":"Clin Park Relat Disord"},{"key":"3288_CR22","first-page":"100161","volume":"7","author":"SH Isaacson","year":"2022","unstructured":"Isaacson SH, Pagan FL, Lew MF, Pahwa R (2022b) Should on-demand treatments for Parkinson\u2019s disease OFF episodes be used earlier? Clin Park Relat Disord 7:100161","journal-title":"Clin Park Relat Disord"},{"key":"3288_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/nmt-2022-0038","volume":"13","author":"SH Isaacson","year":"2023","unstructured":"Isaacson SH, Bowling A, Zhang I et al (2023) Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. Neurodegener Dis Manag 13:75\u201384","journal-title":"Neurodegener Dis Manag"},{"key":"3288_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00702-023-02636-3","volume":"130","author":"WJ Jost","year":"2023","unstructured":"Jost WJ, Kulisevsky J, LeWitt PA (2023) Inhaled levodopa for threatening impending OFF episodes in managing Parkinson\u2019s disease. J Neural Transm (Vienna) 130:821\u2013826","journal-title":"J Neural Transm (Vienna)"},{"key":"3288_CR25","doi-asserted-by":"publisher","first-page":"175628642312092","DOI":"10.1177\/17562864231209240","volume":"16","author":"J Kassubek","year":"2023","unstructured":"Kassubek J, Stocchi F, Martinez EB et al (2023) Feasibility of home dose optimization of apomorphine sublingual film in Parkinson\u2019s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study. Ther Adv Neurol Disord 16:17562864231209240","journal-title":"Ther Adv Neurol Disord"},{"key":"3288_CR26","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1007\/s00415-024-12323-2","volume":"271","author":"J Kassubek","year":"2024","unstructured":"Kassubek J, Factor SA, Balaguer E et al (2024) Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson\u2019s disease complicated by OFF episodes: a phase 3, open-label study. J Neurol 271:3554\u20133570","journal-title":"J Neurol"},{"key":"3288_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759","journal-title":"Lancet Neurol"},{"key":"3288_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mds.27882","volume":"35","author":"HJ Kim","year":"2020","unstructured":"Kim HJ, Jeon BS, Paek SH et al (2020) Incidence of motor complications in Parkinson\u2019s disease. Mov Disord 35:185\u2013190","journal-title":"Mov Disord"},{"key":"3288_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","volume":"41","author":"VS Kostic","year":"1991","unstructured":"Kostic VS, Przedborski S, Flaster E, Sternic N (1991) Early development of motor complications. Neurology 41:202\u2013205","journal-title":"Neurology"},{"key":"3288_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41531-022-00421-9","volume":"8","author":"B Labeit","year":"2022","unstructured":"Labeit B, Berkovich E, Claus I et al (2022) Dysphagia for medication in Parkinson\u2019s disease. NPJ Parkinsons Dis 8:156","journal-title":"NPJ Parkinsons Dis"},{"issue":"9","key":"3288_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00415-025-13390-9","volume":"272","author":"C Ledda","year":"2025","unstructured":"Ledda C, Imbalzano G, Scaglia E et al (2025) Nonmotor fluctuations in Parkinson\u2019s disease: impact on caregiving and quality of life. J Neurol 272(9):639","journal-title":"J Neurol"},{"key":"3288_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA (2015) Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord 30:64\u201372","journal-title":"Mov Disord"},{"key":"3288_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JPD-230055","volume":"13","author":"PA LeWitt","year":"2023","unstructured":"LeWitt PA, Martinez-Nunez P (2023) Drugs to the rescue: comparison of on-demand therapies for OFF symptoms in Parkinson\u2019s disease. J Parkinsons Dis 13:441\u2013451","journal-title":"J Parkinsons Dis"},{"key":"3288_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hauser RA, Pahwa R et al (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145\u2013154","journal-title":"Lancet Neurol"},{"key":"3288_CR35","first-page":"360ra136","volume":"12","author":"MM Lipp","year":"2016","unstructured":"Lipp MM, Batycky R, Moore J et al (2016) Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med 12:360ra136","journal-title":"Sci Transl Med"},{"issue":"1","key":"3288_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41531-022-00331-w","volume":"8","author":"M L\u00f6hle","year":"2022","unstructured":"L\u00f6hle M, Bremer A, Gandor F et al (2022) Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):69","journal-title":"NPJ Parkinsons Dis"},{"key":"3288_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.14802\/jmd.20079","volume":"14","author":"M Lubomski","year":"2021","unstructured":"Lubomski M, Davis RL, Sue CM (2021) Health-related quality of life for Parkinson\u2019s disease patients and their caregivers. J Mov Disord 14:42\u201352","journal-title":"J Mov Disord"},{"key":"3288_CR38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"F Martinez-Fernandez","year":"2016","unstructured":"Martinez-Fernandez F, Schmitt E, Martinez-Martin P, Krack P (2016) The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations. Mov Disord 31:1080\u20131094","journal-title":"Mov Disord"},{"key":"3288_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00002826-199704000-00008","volume":"20","author":"M Merello","year":"1997","unstructured":"Merello M, Pikielny R, Cammarota A, Leiguarda R (1997) Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson\u2019s disease patients: a double-blind single-dose study. Clin Neuropharmacol 20:165\u2013167","journal-title":"Clin Neuropharmacol"},{"key":"3288_CR40","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow CW, Kieburtz K, Rascol O et al (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord 28:1064\u20131071","journal-title":"Mov Disord"},{"key":"3288_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149","journal-title":"Lancet Neurol"},{"key":"3288_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","volume":"19","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Factor SA, Espay AJ et al (2020) Apomorphine sublingual film for off episodes in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 19:135\u2013144","journal-title":"Lancet Neurol"},{"key":"3288_CR43","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F (2021) On-demand therapy for OFF episodes in Parkinson\u2019s disease. Mov Disord 36:2244\u20132253","journal-title":"Mov Disord"},{"key":"3288_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JPD-150764","volume":"6","author":"C Ossig","year":"2016","unstructured":"Ossig C, Sippel D, Fauser M et al (2016) Assessment of nonmotor fluctuations using a diary in advanced Parkinson\u2019s disease. J Parkinsons Dis 6:597\u2013607","journal-title":"J Parkinsons Dis"},{"key":"3288_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/JPD-160996","volume":"7","author":"C Ossig","year":"2017","unstructured":"Ossig C, Sippel D, Fauser M et al (2017) Timing and kinetics of nonmotor fluctuations in advanced Parkinson\u2019s disease. J Parkinsons Dis 7:325\u2013330","journal-title":"J Parkinsons Dis"},{"key":"3288_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jns.2007.03.013","volume":"258","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Koller WC, Trosch RM et al (2007) Subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 258:137\u2013143","journal-title":"J Neurol Sci"},{"key":"3288_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40120-023-00486-5","volume":"12","author":"R Pahwa","year":"2023","unstructured":"Pahwa R, Pagan FL, Kremens DE, Saint-Hilaire M (2023) Clinical use of on-demand therapies for patients with Parkinson\u2019s disease and OFF periods. Neurol Ther 12:1033\u20131049","journal-title":"Neurol Ther"},{"key":"3288_CR48","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40265-020-01307-x","volume":"80","author":"J Paik","year":"2020","unstructured":"Paik J (2020) Levodopa inhalation powder: a review in Parkinson\u2019s disease. Drugs 80:821\u2013828","journal-title":"Drugs"},{"key":"3288_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/17474124.2020.1769475","volume":"14","author":"B Patel","year":"2020","unstructured":"Patel B, Legacy J, Hegland KW et al (2020) A comprehensive review of the diagnosis and treatment of Parkinson\u2019s disease dysphagia and aspiration. Expert Rev Gastroenterol Hepatol 14:411\u2013424","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3288_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","volume":"13","author":"RF Pfeiffer","year":"2007","unstructured":"Pfeiffer RF, Gutmann L, Hull KL Jr. et al (2007) Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease. Parkinsonism Relat Disord 13:93\u2013100","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parkreldis.2020.05.001","volume":"76","author":"RF Pfeiffer","year":"2020","unstructured":"Pfeiffer RF, Isaacson SH, Pahwa R (2020) Clinical implications of gastric complications on levodopa treatment in Parkinson\u2019s disease. Parkinsonism Relat Disord 76:63\u201371","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00455-017-9831-1","volume":"33","author":"C Pflug","year":"2018","unstructured":"Pflug C, Bihler M, Emich K et al (2018) Critical dysphagia is common in Parkinson disease and occurs even in early stages: a prospective cohort study. Dysphagia 33:41\u201350","journal-title":"Dysphagia"},{"key":"3288_CR53","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H","volume":"15","author":"W Poewe","year":"2000","unstructured":"Poewe W, Wenning GK (2000) Apomorphine: an underutilized therapy for Parkinson\u2019s disease. Mov Disord 15:789\u2013794","journal-title":"Mov Disord"},{"key":"3288_CR54","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"key":"3288_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-017-8473-7","volume":"20","author":"C Politi","year":"2018","unstructured":"Politi C, Ciccacci C, Novelli G, Borgiani P (2018) Genetics and treatment response in Parkinson\u2019s disease: an update on pharmacogenetic studies. Neuromolecular Med 20:1\u201317","journal-title":"Neuromolecular Med"},{"key":"3288_CR56","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S et al (2010) Parkinson\u2019s disease symptoms and quality of life. Mov Disord 25:1646\u20131651","journal-title":"Mov Disord"},{"issue":"10","key":"3288_CR57","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/mdc3.14198","volume":"11","author":"LG Ramanzini","year":"2024","unstructured":"Ramanzini LG, Frare JM, Camargo LFM et al (2024) Does delaying levodopa prevent motor complications in Parkinson\u2019s disease? A meta-analysis. Mov Disord Clin Pract Oct 11(10):1195\u20131202","journal-title":"Mov Disord Clin Pract Oct"},{"key":"3288_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00702-025-02990-4","volume":"133","author":"M Regensburger","year":"2026","unstructured":"Regensburger M, Csoti I, Jost WH et al (2026) Motor and non-motor fluctuations in Parkinson\u2019s disease: the knowns and unknowns of current therapeutic approaches. J Neural Transm (Vienna) 133:309\u2013324","journal-title":"J Neural Transm (Vienna)"},{"key":"3288_CR59","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T et al (2025) Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm (Vienna) 132:743\u2013779","journal-title":"J Neural Transm (Vienna)"},{"key":"3288_CR60","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos A, Martinez-Martin P, Odin P et al (2014) Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat Disord 20:1231\u20131235","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/mdc3.13122","volume":"8","author":"C Rodriguez-Blazquez","year":"2020","unstructured":"Rodriguez-Blazquez C, Schrag A, Rizos A et al (2020) Prevalence of non-motor symptoms and non-motor fluctuations in Parkinson\u2019s disease using the MDS-NMS. Mov Disord Clin Pract 8:231\u2013239","journal-title":"Mov Disord Clin Pract"},{"key":"3288_CR62","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM et al (2021) Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann Neurol 90:52\u201361","journal-title":"Ann Neurol"},{"key":"3288_CR63","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinthera.2020.04.004","volume":"42","author":"BE Safirstein","year":"2020","unstructured":"Safirstein BE, Ellenbogen A, Zhao P et al (2020) Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson\u2019s disease. Clin Ther 42:1034\u20131046","journal-title":"Clin Ther"},{"key":"3288_CR64","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson\u2019s disease. Brain 123:2297\u20132305","journal-title":"Brain"},{"key":"3288_CR65","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109","journal-title":"Lancet Neurol"},{"key":"3288_CR67","doi-asserted-by":"publisher","first-page":"837e46","DOI":"10.1007\/s00702-010-0424-5","volume":"117","author":"M Stacy","year":"2010","unstructured":"Stacy M (2010) The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson\u2019s disease. J Neural Transm 117:837e46","journal-title":"J Neural Transm"},{"key":"3288_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.parkreldis.2007.07.013","volume":"14","author":"MA Stacy","year":"2008","unstructured":"Stacy MA, Murphy JM, Greeley DR et al (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14:205\u2013212","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR68","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Antonini A, Barone P et al (2014) Early Detection of wearing off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20:204\u2013211","journal-title":"Parkinsonism Relat Disord"},{"key":"3288_CR69","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3233\/JPD-230072","volume":"13","author":"F Stocchi","year":"2023","unstructured":"Stocchi F, Rascol O, Poewe W et al (2023) Apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson\u2019s disease: an open-label, randomized, crossover study. J Parkinsons Dis 13:1329\u20131342","journal-title":"J Parkinsons Dis"},{"key":"3288_CR70","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease. Neurology 80:800\u2013809","journal-title":"Neurology"},{"key":"3288_CR71","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.23517","volume":"26","author":"R Stowe","year":"2011","unstructured":"Stowe R, Ives N, Clarke CE (2011) Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson\u2019s disease. Mov Disord 26:587\u2013598","journal-title":"Mov Disord"},{"key":"3288_CR72","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00455-015-9671-9","volume":"31","author":"I Suttrup","year":"2016","unstructured":"Suttrup I, Warnecke T (2016) Dysphagia in Parkinson\u2019s disease. Dysphagia 31:24\u201332","journal-title":"Dysphagia"},{"issue":"4","key":"3288_CR73","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"24","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur CVM, Suwijn SR, Boel JA et al (2019) Randomized delayed-start trial of levodopa in Parkinson\u2019s Disease. N Engl J Med Jan 24(4):315\u2013324","journal-title":"N Engl J Med Jan"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03288-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:07:16Z","timestamp":1790255236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03288-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":73,"alternative-id":["3288"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03288-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}